簡單介紹

吳一諾 博士，副教授，博士生導師。2006年本科畢業于中山大學化學與化學工程學院應用化學專業。2011年畢業于太阳集团1088vip藥物化學專業，獲理學博士學位。2011年至2013年于香港理工大學應用生物與化學科技系進行博士後研究。2013年加入太阳集团1088vip。主要從事"靶向磷酸二酯酶的原創候選藥物發現及其在纖維化疾病中的應用"。目前已在 J. Med.Chem, Acta Pharma. Sin. B. Org. Lett., Chem.Commun.等國際權威雜志發表高水平收錄論文60餘篇。共主持國家自然科學基金等項目9項，并作為課題骨幹參與國家科技部重點研發計劃。

 

教育經曆

2006/09 - 2011/06，中山大學，太阳集团1088vip，藥物化學，博士

2002/09 - 2006/06，中山大學，化學與化學工程學院，應用化學系，學士

 

工作經曆

2018/04- 至今，中山大學，太阳集团1088vip，副教授

2013/07 - 2018/04，中山大學，太阳集团1088vip，講師

2011/07 - 2013/06，香港理工大學，應用生物與化學科技系，博士後

 

 

教學情況

中山大學第十一屆教師教學競賽理科組特等獎

《現代分析技術與應用》

《基礎化學》

《大學化學實驗》

科研項目

1. 國家自然科學基金面上項目，抗血管性癡呆嘧啶酮類PDE1選擇性抑制劑的結構優化與作用機制研究，項目編号：22377155；2024.01 - 2027.12; 50萬元

2. 國家自然科學基金面上項目，選擇性磷酸二酯酶9型抑制劑的成藥性優化及抗肺纖維化作用研究，項目編号：21977127；2020.01 - 2023.12; 66萬元

3. 廣東省自然科學基金面上項目，高選擇性磷酸二酯酶9型抑制劑的設計、成藥性優化及其抗血管性癡呆作用研究，項目編号：2019A1515011883；2019.01 - 2022.12; 10萬元

4. 廣州市科技計劃項目珠江科技新星專題，新型萘内酰亞胺類磷酸二酯酶二型抑制劑的合理化設計、合成及其抗阿爾茨海默症藥效研究，2018.01 - 2020.12；30萬元。

5. 國家自然科學基金青年項目，钯催化下甲苯類酰化試劑參與的鄰位和間位C-H酰基化反應，項目編号：21402243；2015.01 - 2017.12; 25萬元

6. 中山大學青年教師培育基金，C-H鍵磷酯方法高效構建苯（雜）環類有機磷化合物新型方法研究，項目編号：13ykpy10；2013.11 - 2016.12；15萬元。

7. 國家重點研發計劃，課題骨幹，基于E 級高性能計算生物醫藥應用軟件系統研制及應用。課題四：癌症、糖尿病與感染性疾病新藥研究與軟件應用驗證, 課題編号：2017YFB0202604; 2017.07 - 2020.12; 749萬元。
 

 

 

論著專利

  

  1. Zhou, Q. #; Le, M.#; Yang, Y.; Wang W.; Huang, Y.; Wang, Q.; Tian, Y.; Jiang, M.; Rao Y.*; Luo, H.-B.*; Wu, Yinuo*, Discovery of novel phosphodiesterase-1 inhibitors for curing vascular dementia: Suppression of neuroinflammation by blocking NF-κB transcription regulation and activating cAMP/CREB axis.  Acta Pharmaceutica Sinica B. 2023, 13, 1180-1191.(中科院醫學一區，Top)
  2. Zhang, B. #;  Yang, Y.#; Zhao, Z-J.#; Wang W.; Huang, Y.; Wang, Q.; Tian, Y.; Jiang, M.; Wang, Q.*; Luo, H.-B.*; Wu, Yinuo*, Identification of novel quinolin-2(1H)-ones as phosphodiesterase 1 inhibitors for the treatment of inflammatory bowel disease. Journal of Medicinal Chemistry. 2023, 66, 12468.(中科院醫學一區，Top)
  3. Huang, M. X. #; Tian, Y. J. #; Han, C.; Liu, R. D.; Xie, X.; Yuan, Y.; Yang, Y. Y.; Li, Z.; Chen, J.;* Luo, H. B.*; Wu, Yinuo*. Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects. Journal of Medicinal Chemistry. 2022, 65, 8444-8455. (中科院醫學一區，Top)
  4. Wu, X.-N.#; Qian, Z. #; Huang, Y.-D.; Xie X; Li Z; Wu, Yinuo*; Luo, H.-B.*, Structure-based discovery of orally efficient inhibitors via unique interactions with H-pocket of PDE8 for the treatment of vascular dementia. Acta Pharm. Sin. B 2022, 12, 3103-3112. (中科院醫學一區，Top)
  5. Wu Y, Wang Q, Jiang MY, Huang YY, Zhu Z, Han C, et al. Discovery of Potent Phosphodiesterase-9 Inhibitors for the Treatment of Hepatic Fibrosis. Journal of Medicinal Chemistry. 2021;64, 9537-49. (中科院醫學一區，Top)
  6. Wu Y#, Li Z, Yun-Song Zhao, et al. Therapeutic targets and potential agents for the treatment of COVID-19. Med Res Rev, 2021, 41, 1775-1797. (中科院醫學一區)
  7. Wu, Y.;  Tian, Y. J.;  Le, M. L.;  Zhang, S. R.;  Zhang, C.;  Huang, M. X.;  Jiang, M. Y.;  Zhang, B.; Luo, H. B., Discovery of Novel Selective and Orally Bioavailable Phosphodiesterase-1 Inhibitors for the Efficient Treatment of Idiopathic Pulmonary Fibrosis. Journal of Medicinal Chemistry. 2020, 63, 7867-7879. (中科院醫學一區，Top)
  8. Wu, Yinuo#; Zhou, Q.#; Zhang, T.#; Li, Z.; Chen, Y. P.; Zhang, P.; Yu, Y. F.; Geng, H.; Tian, Y. J.; Zhang, C.; Wang, Y.; Chen, J. W. *; Chen, Y. *; Luo, H. B. *, Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia. Journal of Medicinal Chemistry. 2019, 62, 4218-4224. (中科院醫學一區，Top)
  9. Huang, Y. Y.; Yu, Y. F.; Zhang, C.; Chen, Y.; Zhou, Q.; Li, Z.; Zhou, S.; Li, Z.; Guo, L.; Wu, D. *; Wu, Yinuo;*; Luo, H. B. *, Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors. Journal of Medicinal Chemistry. 2019, 62, 3707-3721. (中科院醫學一區，Top)
  10. Wu, Yinuo; Li, Z.; Huang, Y.-Y.; Wu, D.; Luo, H.-B. *, Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease. Journal of Medicinal Chemistry. 2018, 61, 5467-5483.(中科院醫學一區，Top)
  11. Wu, X. N.; Huang, Y. D.; Li, J.; Yu, Y.-F.;Zhou, Q.; Zhang, C.; Wu, Yinuo* and Luo, H.-B.* Structure-based design, synthesis, and biological evaluation of novel pyrimidinone derivatives as PDE9 inhibitors. Acta Pharmaceutica Sinica B. 2018, 8, 615-628.(中科院醫學一區，Top)
  12. Li, J.; Chen, J.-Y.; Deng, Y.-L.; Zhou, Q.; Wu, Yinuo*; Wu, D. *; Luo, H.-B., Structure-based design, synthesis, biological evaluation, and molecular docking of novel PDE10 inhibitors with antioxidant activities. Front. Chem. 2018, 6, 167/1-167/12.
  13. Zhang, C.; Zhou, Q.; Wu, X. N.; Huang, Y. D.; Zhou, J.; Lai, Z.; Wu, Yinuo*; Luo, H.-B. Discovery of novel PDE9A inhibitors with antioxidant activities for treatment of Alzheimer’s disease. J. Enzym. Inhib. Med. Chem. 2018, 33 (1), 260-270.
  14. Yu, Y. F.; Huang, Y. D.; Zhang, C; Wu, X. N.; Zhou, Q; Wu, D. Y.; Wu, Yinuo*;  Luo, H. B. * Discovery of Novel Pyrazolopyrimidinone Derivatives as  Phosphodiesterase 9A Inhibitors Capable of Inhibiting  Butyrylcholinesterase for Treatment of Alzheimer's Disease. ACS Chem. Neurosci. 2017, 8, 2522.
  15. .Zhang, C; Feng, L. J.; Huang, Y. Y.; Wu, D. Y.; Li, Z.; Zhou, Q.; Wu, Yinuo*;  Luo,  H. B.* Discovery of Novel Phosphodiesterase-2A Inhibitors by  Structure-Based Virtual Screening, Structural Optimization, and  Bioassay. J. Chem. Inf. Model. 2017, 57, 355.
  16. Wu, Yinuo;  Jiang, C.; Wu, D.; Gu, Q.; Luo, Z. Y.; Luo, H. B.*. Palladium-catalyzed  C–H bond carboxylation of acetanilides: an efficient usage of N,  N-dimethyloxamic acid as the carboxylate source. Chem. Commun. 2016, 52, 1286.
  17. Wu, Yinuo; Sun, L.; Chen, Y.; Zhou, Q.; Huang, J. W.; Miao, H.; Luo, H. B.* Palladium-catalyzed decarboxylative acylation of N-nitrosoanilines with α-oxocarboxylic acids. J. Org. Chem.2016, 81, 1244.
  18. Cai, Y. H.; Guo, Y.; Li, Z.;Wu, D.; Li, X.; Zhang, H.; Yang, J.; Lu, H.; Sun. Z.; Luo, H. B.; Yin, S.*;  Wu, Yinuo*. Discovery and modelling studies of natural ingredients from Gaultheria yunnanensis (FRANCH.) against phosphodiesterase-4. Eur. J. Med. Chem. 2016, 114, 134.
  19. Li, Z.; Lu, X.; Feng, L.-J.; Gu, Y.; Li, X.; Wu, Yinuo*; Luo, H.-B.* Molecular dynamics-based discovery of novel phosphodiesterase-9A inhibitors with non-pyrazolopyrimidinone scaffolds. Mol. BioSyst. 2015, 11, 115.
  20. Wu, Yinuo; Feng, L. J.; Lu, X.; Kwong, F. Y.*; Luo, H. -B.*. Palladium-catalyzed oxidative C–H bond acylation of N-nitrosoanilines with toluene derivatives: a traceless approach to synthesize N-alkyl-2-aminobenzophenones. Chem. Commun. 2014, 50, 15352.
  21. Wu, Yinuo; Choy P. Y., Mao F., Kwong F. Y.* Toluene Derivatives as Simple Coupling Precursors for Cascade Palladium-Catalyzed Oxidative C-H bond Acylation of Acetanilides. Chem. Commun. 2013, 49, 689.
  22. Wu, Yinuo; Wong, S. M.; Mao, F.; Chan, T. L.; Kwong, F. Y. * Intramolecular Direct C-H Bond Arylation from Aryl Chlorides: A Transition-Metal-Free Approach for Facile Access of Phenanthridines. Org. Lett. 2012, 14, 5306.
  23. Wu, Yinuo; Wang, J.; Li, P. *; Kwong, F. Y.* Catalyst-free efficient aza-michael addition of azoles to nitroalkenes, Synlett, 2012, 23, 788
  24. Wu, Yinuo; Li, B.; Mao, F.; Li, X.;* Kwong, F. Y.* Palladium -Catalyzed Oxidative C-H Bond Coupling of Steered Acetanilides and Aldehydes: A Facile Access to ortho-Acylacetanilide. Org. Lett. 2011, 13, 3258.
  25. Wu, Yinuo; Mao, F.; Meng, F.; Li. X.* Enantioselective Vanadium-Catalyzed Oxidation of 1,3-Dithianes from Aldehydes and Ketones using beta-Amino Alcohol Derived Schiff Base Ligands. Adv. Synth.Catal. 2011, 353, 1707.